Akèy › Emofili B
Etid klinik pou Emofili B ap rekrite nan Etazini
12 etid pou Emofili B ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Philadelphia, PA5 etid
- Los Angeles, CA4 etid
- Sacramento, CA4 etid
- Atlanta, GA4 etid
- Houston, TX4 etid
- Ann Arbor, MI4 etid
- Nashville, TN3 etid
- Greenville, NC3 etid
- Gainesville, FL3 etid
- San Francisco, CA3 etid
- Seattle, WA3 etid
Pa eta
- Florid4 etid
- Georgia4 etid
- Kalifòni7 etid
- Lwizyàn3 etid
- Michigan6 etid
- Missouri3 etid
- New York5 etid
- North Carolina4 etid
- Ohio3 etid
- Pennsylvania6 etid
- Tennessee4 etid
- Texas4 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Ap rekriteFaz 3
Laj 1 a 17 · Gason · Mizajou Sep 23, 2026 · NCT05611801Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Ap rekriteFaz 3
138 Months – 206 Months · Gason · Mizajou Sep 16, 2026 · NCT07080905A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Ap rekriteFaz 1/2
Laj 2 ak plis · Gason · Mizajou Sep 11, 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT06003387SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Ap rekriteFaz 3
Laj 6 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT04563520ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 60 · Tout sèks · Mizajou Jul 2, 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Ap rekriteFaz 3
Laj 1 a 74 · Gason · Mizajou Jul 1, 2026 · NCT05145127Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou May 27, 2026 · NCT05568719ATHNdataset Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Apr 21, 2026 · NCT06820515An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 19, 2026 · NCT06008938SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Ap rekriteFaz 4
Laj 12 a 100 · Tout sèks · Mizajou Jan 12, 2026 · NCT04647227Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.